姜标课题组介绍
姜标Co-PI：陈红莉 |
|
姜标，亚洲太阳sungame 通讯地址：人字楼A407 电子邮件：jiangbiao@shanghaitech.edu.cn chenhl@shanghaitech.edu.cn 个人简历： 国际欧亚科学院院士；中科院曼谷创新合作中心主任；上海标新医药生物创始人；曾任中国科学院上海有机化学研究所所长、中国科学院上海高等研究院副院长、上海科技大学免疫化学研究所执行所长。曾获得2项国家科技进步二等奖、2项求是奖、2项中国产学研奖、联合国环境规划署环境保护杰出成就奖、中国科学院科学杰出贡献奖等40多项奖励；为我国履行《关于汞的水俣公约》、《蒙德利尔议定书》和《巴黎气候条约》做出积极贡献。发表学术论文300余篇，申请专利200余项；欧美德日等国专利10余项，近60多项专利转让或授权企业转化。作为副主编出版《中药天然产物大全》（12卷，约3000万字）。
|
抗体药物偶联物、蛋白降解技术 |
本课题组致力于创新药物研究，是一个集化学、生物学及药学多学科交叉的实验室，侧重于抗体药物偶联物(Antibody-Drug Conjugates)和蛋白降解技术(Protelysis Targeting Drug) 核心技术的建立，聚焦于尖端药物的研究和开发。 |
1. Ren, C.; Sun, N.; Liu, H.; Kong, Y.; Sun, R.; Qiu, X.; Chen, J.; Li, Y.; Zhang, J.; Zhou, Y.; Zhong, H.; Yin, Q.; Song, X.; Yang, X.; Jiang, B., Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. J Med Chem 2021,64, 9152-9165. 2. Rong, H.; Shen, Y.; Xu, Z.; Wei, D.; Song, X.; Jiang, B.; Chen, H., Combretastatin A4-derived payloads for antibody-drug conjugates. Eur J Med Chem 2021,216, 113355. 3. Liu, H.; Sun, R.; Ren, C.; Qiu, X.; Yang, X.; Jiang, B., Construction of an IMiD-based azide library as a kit for PROTAC research. Org Biomol Chem 2021,19, 166-170. 4. Ren, C.; Sun, N.; Kong, Y.; Qu, X.; Liu, H.; Zhong, H.; Song, X.; Yang, X.; Jiang, B., Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. Eur J Med Chem 2021,217, 113335. 5. Qu, X.; Liu, H.; Song, X.; Sun, N.; Zhong, H.; Qiu, X.; Yang, X.; Jiang, B., Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems. Eur J Med Chem 2021,218, 113328. 6. Wei, D.; Mao, Y.; Xu, Z.; Chen, J.; Li, J.; Jiang, B.; Chen, H., Site-specific construction of triptolide-based antibody-drug conjugates. Bioorgan Med Chem 2021,51, 116497. 7. Huang, R.; Zhu, W.; Xu, Z.; Chen, J.; Jiang, B.; Chen, H.; Chen, W., Accurate Retention Time Prediction Based on Monolinked Peptide Information to Confidently Identify Cross-Linked Peptides. J Am Soc Mass Spectr 2021,32, 2410-2416. 8. Huang, R.; Sheng, Y.; Wei, D.; Lu, W.; Xu, Z.; Chen, H.; Jiang, B., Divinylsulfonamides enable the construction of homogeneous antibody–drug conjugates. Bioorgan Med Chem 2020,28, 115793. 9. Huang, R.; Gao, X.; Xu, Z.; Zhu, W.; Wei, D.; Jiang, B.; Chen, H.; Chen, W., Decision tree searching strategy to boost the identification of cross-linked peptides. Anal Chem 2020,92, 13702-13710. 10. Sun, N.; Ren, C.; Kong, Y.; Zhong, H.; Chen, J.; Li, Y.; Zhang, J.; Zhou, Y.; Qiu, X.; Lin, H.; Song, X.; Yang, X.; Jiang, B., Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Eur J Med Chem 2020,193, 112190. 11. Huang, R.; Sheng, Y.; Wei, D.; Yu, J.; Chen, H.; Jiang, B., Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates. Eur J Med Chem 2020,190, 112080. 12. Huang, R.; Li, Z.; Yu, J.; Chen, H.; Jiang, B., H2O-Regulated Chemoselectivity in Oxa- Versus Aza-Michael Reactions. Org Lett 2019,21, 4159-4162. 13. Qiu, X.; Sun, N.; Kong, Y.; Li, Y.; Yang, X.; Jiang, B., Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction. Org Lett 2019,21, 3838-3841. 14. Zhao, Q.; Ren, C.; Liu, L.; Chen, J.; Shao, Y.; Sun, N.; Sun, R.; Kong, Y.; Ding, X.; Zhang, X.; Xu, Y.; Yang, B.; Yin, Q.; Yang, X.; Jiang, B., Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem 2019,62, 9281-9298. 15. Huang, R.; Zhu, W.; Wu, Y.; Chen, J.; Yu, J.; Jiang, B.; Chen, H.; Chen, W., A novel mass spectrometry-cleavable, phosphate-based enrichable and multi-targeting protein cross-linker. Chem Sci 2019,10, 6443-6447. |
陈红莉 Co-PI 阴倩倩 宋肖玲 杨异凤
副研究员 助理研究员 助理研究员 助理研究员
